The Center for Biosimilars® recaps the top 5 biosimilars articles for the week of April 2, 2018.
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of April 2.
Number 5: A recently published descriptive review finds a significant time lag between the approval of biosimilar infliximab and its acceptance in Irish hospitals.
Number 4: The Senate Homeland Security and Government Affairs Committee has released a report on prescription drug price increases that affect drugs that seniors use most. According to the report, drug prices rise at approximately 10 times the rate of inflation.
Number 3: CMS will lower the maximum co-payment amount for low-income subsidy beneficiaries for biosimilars.
Number 2: Samsung Bioepis and Biogen have reached a settlement with AbbVie that will allow the biosimilar adalimumab, Imraldi, to launch in Europe later this year.
Number 1: Celltrion has announced that the FDA has issued Complete Response Letters for 2 of its proposed biosimilar products.
Also this week, expert contributor Sonia T. Oskouei explains 9 key facts about biosimilar interchangeability in the United States.
Finally, last week, our e-newsletter asked whether you think one payer’s recent decision not to undertake a nonmedical switch to a biosimilar is good news for patients.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.